## Exhibit 8

	Page 1
1	UNITED STATES DISTRICT COURT
2	NORTHERN DISTRICT OF OHIO
3	EASTERN DIVISION
4	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
5	IN RE: NATIONAL PRESCRIPTION MDL No. 2804
	OPIATE LITIGATION
6	Case No.
	17-md-2804
7	
	Judge Dan Aaron
8	Polster
9	This document relates to:
10	The County of Cuyahoga v. Purdue Pharma, et
	al., Case No. 17-0P-45004
11	
	City of Cleveland, Ohio v. Purdue Pharma L.P.,
12	et al., Case No. 18-OP-45132
13	The County of Summit, Ohio, et al. v. Purdue
	Pharma L.P., et al., Case No. 18-OP-45090
14	
	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
15	
16	
	Videotaped Deposition of
17	GERALD CRAIG
18	January 11, 2018
	9:12 a.m.
19	
20	Taken at:
21	Jackson Kelley, PLLC
	50 South Main Street, Suite 201
22	Akron, Ohio
23	
24	
25	Stephen J. DeBacco, RPR

```
Page 2
    APPEARANCES:
1
2
           On behalf of the City of Akron, Summit
3
           County, and the Witness:
4
                 Motley Rice LLC, by
5
                 ANNE MCGINNESS KEARSE, ESQ.
                 JODI WESTBROOK FLOWERS, ESQ.
                 ANNIE E. KOUBA, ESQ.
6
                 DANIELLE M. SALERNO, ESQ.
                 28 Bridgeside Boulevard
7
                 Mt. Pleasant, South Carolina 29464
8
                 (843) 216-9140
                 akearse@motleyrice.com
                 (843) 216-9163
9
                 jflowers@motleyrice.com
                 (843) 216-9225
10
                 akouba@motleyrice.com
11
                 (843) 216-9461
                 dsalerno@motleyrice.com
12
13
           On behalf of Cardinal Health:
14
                 Williams & Connolly, by
15
                 PAUL E. BOEHM, ESQ.
                 MELINDA JOHNSON, ESQ.
16
                 Williams & Connolly LLP
                 725 Twelfth Street Northwest
17
                 Washington, D.C. 20005
                 (202) 434-5366
18
                 pboehm@wc.com
                 (202) 434-5181
19
                 mkjohnson@wc.com
20
21
22
23
24
25
```

```
Page 3
    APPEARANCES, Continued:
1
2
           On behalf of Cephalon, Inc.; Teva
3
           Pharmaceuticals USA, Inc.; Actavis, LLC;
           Actavis Pharma, Inc. f/k/a Watson Pharma,
           Inc.; and Watson Laboratories, Inc.:
                 Morgan, Lewis & Bockius LLP, by
5
                 WENDY WEST FEINSTEIN, ESQ.
                 One Oxford Centre, 32nd Floor
6
                 Pittsburgh, Pennsylvania 15219-6401
                 (412) 560-7455
7
                 wendy.feinstein@morganlewis.com
8
           On behalf of Endo Health Solutions, Inc.,
           and Endo Pharmaceuticals, Inc.:
10
                 Baker Hostetler, by
11
                 CAROLE S. RENDON, ESQ.
                 Key Tower
12
                 127 Public Square, Suite 2000
                 Cleveland, Ohio 44114-1214
                 (216) 861-7420
13
                 crendon@bakerlaw.com
14
15
           On behalf of Johnson & Johnson and
           Janssen Pharmaceuticals, Inc.:
16
                 Tucker Ellis, LLP, by
                 BRENDA A. SWEET, ESQ.
17
                 950 North Main Avenue, Suite 1100
                 Cleveland, Ohio 44113
18
                 (216) 696-2493
19
                 brenda.sweet@tuckerellis.com
20
21
22
23
24
2.5
```

```
Page 4
    APPEARANCES, Continued:
1
2
 3
           On behalf of CVS Rx Services, Inc., and
           CVS Indiana, LLC:
 4
                 Zuckerman Spaeder LLP, by
                 DANIEL P. MOYLAN, ESQ.
5
                 100 East Pratt Street, Suite 2440
                 Baltimore, Maryland 21202-1031
 6
                 (410) 949-1159
 7
                 dmoylan@zuckerman.com
 8
           On behalf of Walmart, Inc.:
9
                 Jones Day, by
                 MEREDITH C. KINCAID, ESQ.
10
                 1420 Peachtree Street Northeast
11
                 Suite 800
                 Atlanta, Georgia 30309-3053
12
                 (404) 581 - 8043
                 mkincaid@jonesday.com
13
           On behalf of Cardinal Health, via
14
           Teleconference:
15
                 Williams & Connolly, LLP, by
                 BRAD MASTERS, ESQ.
16
                 725 Twelfth Street Northwest
17
                 Washington, D.C. 20005
                 (202) 434-5182
18
                 bmasters@wc.com
19
2.0
21
22
23
24
25
```

```
Page 5
    APPEARANCES, Continued:
1
2
           On behalf of Cephalon, Inc.; Teva
           Pharmaceuticals USA, Inc.; Actavis, LLC;
3
           Actavis Pharma, Inc. f/k/a Watson Pharma,
           Inc.; and Watson Laboratories, Inc., via
4
           teleconference:
5
                 Morgan, Lewis & Bockius LLP, by
                 PAMELA HOLLY, ESQ.
6
                 101 Park Avenue
7
                 New York, New York 10178-0060
                 (212) 309-6864
                 pamela.holly@morganlewis.com
8
9
           On behalf of AmerisourceBergen Drug
           Corporation, via teleconference:
10
11
                 Reed Smith LLP, by
                 KELLY H. HIBBERT, ESQ.
12
                 1301 K Street Northwest, Suite 1000
                 East Tower
13
                 Washington, D.C., 20005
                 (202) 414-9226
                 khibbert@reedsmith.com
14
15
           On behalf of McKesson Corporation:
16
                 Covington & Burling LLP, by
                 PATRICK R. CAREY, ESQ.
17
                 One Front Street
                 San Francisco, California 94111-5356
18
                 (415) 591-7093
19
                 pcarey@cov.com
20
                         ~ ~ ~ ~ ~
21
    ALSO PRESENT:
22
                 Kurt Henschel, Legal Videographer
23
24
2.5
```

	Page 6	
1	TRANSCRIPT INDEX	
2		
3	APPEARANCES	
4		
5	INDEX OF EXHIBITS 7	
6		
7	EXAMINATION OF GERALD CRAIG	
8	By Mr. Boehm	
9	By Ms. Feinstein 404	
L O	By Mr. Moylan 412	
L1	By Ms. Kearse 428	
L 2	By Mr. Boehm 429	
L 3	By Ms. Kearse 429	
L 4	By Mr. Boehm 429	
L 5		
L 6	REPORTER'S CERTIFICATE 432	
L 7		
L 8	EXHIBIT CUSTODY	
L 9	EXHIBITS RETAINED BY THE COURT REPORTER	
2 0		
21		
22		
23		
2 4		
25		

Page 149

- Q. Do you agree with res- -- that with respect to the opioid epidemic, it is important to be able to understand the causes in order to address -- and try and address the problems that exist; is that fair?
- A. That became more and more clear over time, yes.
- Q. Okay. Did Summit County do anything in 2010, the date of this document marked as Exhibit 6, or before 2010 to investigate the causes of the opioid epidemic within Summit County?

MS. KEARSE: Objection to form. Mischaracterizes the testimony.

A. I -- I don't remember if there was anything specific that we did in 2010. Again, that was the -- the year that Bill Harper left and I was appointed as director. At that point in time in our community, we were struggling with methamphetamines and bath salts, I believe were -- were two of the most significant issues that -- that took up a lot of our attention.

But we were getting (information)

from our providers that would indicate that --

that there was an increased demand for services

Page 150 specific to people who are opiate involved. 1 By 2010, right? 2 **O** . Α. 3 Yes. And did you undertake to try and 4 understand -- do you agree -- do you have a 5 view as to whether or not, by 2010, Summit 6 County was experiencing an opioid epidemic? Do I agree or do I understand --8 9 Do you have a view as to whether or Ο. 10 not, by 2010, Summit County was experiencing an opioid epidemic? 11 12 Based on -- based on some information that was provided to us from one of 13 our providers, we were investigating. 14 15 You hadn't made a determination by 16 2010 as to whether or not you had an opioid 17 epidemic on your hands? 18 We were not so much concerned about 19 whether there was an opiate epidemic as we were 20 about whether or not there was a need for 21 increased capacity for services. 22 Q. Do you have a view, Mr. Craiq, as the head of the Summit County ADAMHS Board 23 since 2010, as to whether or not by that year, 24 2010, Summit County was experiencing an opioid 25